Sector News

Convatec shares jump on report of potential takeover interest

March 27, 2019
Life sciences

Shares in Convatec jumped to one-month highs on Tuesday after Swedish business daily Dagens Industri said several investors are considering an offer for the British medical device maker after the recent slump in its stock.

One of the interested parties is Swedish private equity firm EQT, according to the report, which cited anonymous sources.

The FTSE 250-listed shares were up 8.1 percent at 0857 GMT after hitting their highest since mid-February. They were top of the pan-European STOXX 600.

Turnover was high with 4.4 million shares changing hands in the first hour of trading, just shy of the long-term total daily average.

Convatec and EQT declined to comment.

The shares plummeted a month ago after the company launched a turnaround plan following disappointing annual results.

By Josephine Mason

Source: Reuters

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach